Canopy Growth Corporation
CGCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Canopy Growth Corporation focuses on Drug Manufacturers - Specialty & Generic services and products. Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany,. The company carries a $462.6M market cap, placing it firmly in the small-cap category. The company operates through two segments, Cannabis and Storz & Bickel.
Market Cap
$462.6M
Beta
2.43
P/E (TTM)
—
P/E (Fwd)
-7.89
EPS (TTM)
$-0.48
EPS (Fwd)
$-0.12
ROE
-39.5%
ROA
-3.9%
Cash
$337.8M
Total Debt
$277.3M
Free CF
$7.2M
52W Change
-27.9%
Annual Financials
Cash vs Debt
Where CGC stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CGC finished 4.85% below its 150-day moving average ($1.03) and 10.09% below its 200-day moving average ($1.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGC overbought or oversold?
At the September 2, 2026 close, CGC's RSI(14) was 39.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $337.8M in cash and $277.3M in debt, CGC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $7.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -39.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $333.3M (2023) to $284.6M (2026), a 15% decline worth watching.
Canopy Growth Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Canopy Growth Corporation and its sector.